Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: Combined analysis of pooled data from two large randomized observer and patient-masked studies

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2005, Pages 242-249

  Fechtner, Robert D ^a   McCarroll, Kathleen A ^b   Lines, Christopher R ^b   Adamsons, Ingrid A ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIOPHENES; TIMOLOL; TREATMENT OUTCOME;

EID: 21644472486     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.242     Document Type: Article

References (13)

1. Patel, S.S., and Spencer, C.M. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaumcoma and ocular hypertension. Drugs Aging 9:363-378,1996.
2. Ormrod, D., and McClellan, K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 17:477-496, 2000.
3. Fechtner, R.D., Airaksinen, J., Getson, A.J., Lines, C.R., and Adamsons, I.A. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus latanoprost 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 82:42-48, 2004.
4. Emmerich, K.-H. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and hypertension. Graefe's Arch. Clin. Exp. Ophthalmol. 238:19-23, 2000.
5. Honrubia, F.M., Larsson, L.I., Spiegel, D., and European Latanoprost Study Group. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol. Scand. 80:635-641, 2002.
6. Garcia Sanchez, J. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide, to timolol in patients with glaucoma and ocular hypertension - a three-month randomized study. Eur. J. Ophthalmol. 10:198-204, 2000.
7. Konstas, A.G., Papapanos, P., Tersis, I., Houliara, D., and Stewart, W.C. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 110:1357-1360, 2003.
8. Gandolfi, S., Simmons, S.T., Sturm, R., Chen, K., Van-Denburgh, A.M., and Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. 18:110-121, 2001.
9. Polo, V., Larrosa, J.M., Gomez, M.L., Pablo, L., and Honrubia, P.M. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthal. Scand. 76:6-9,2001.
10. Hedman, K., and Aim, A. A pooled analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur. J. Ophthalmol. 10:95-104, 2000.
11. Bron, A.M., and Emmerich, K.-H. Latanoprost versus combined timolol and dorzolamide. Surv. Ophthalmol. 47:S148-S154, 2002.
12. Strohmaier, K., Snyder, E., DuBiner, H., and Adamsons, I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 105:1936-1944, 1998.
13. Higginbotham, E.J., Feldman, R., Stiles, M., Dubiner, H., and Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy. One-year randomized trial. Arch. Ophthalmol. 120:915-922, 2002.